Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Nuvation Bio Inc. Class A (NUVB)
Company Research
Source: Yahoo! Finance
Preliminary IBTROZI net product revenue of approximately $15.7 million in the fourth quarter and $24.7 million since launch Preliminary unaudited cash, cash equivalents and marketable securities of approximately $529.2 million as of December 31, 2025 Company to present at 44 th Annual J.P. Morgan Healthcare Conference tomorrow, January 13, at 3:45 p.m. PT/6:45 p.m. ET NEW YORK, January 12, 2026 BUSINESS WIRE )--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced preliminary fourth quarter and full year 2025 net product revenue for IBTROZI ® (taletrectinib) and provided a 2026 outlook ahead of its presentation at the 44 th Annual J.P. Morgan Healthcare Conference in San Francisco, CA Preliminary Fourth Quarter and Full Year 2025 Financial Results and IBTROZI Commercial Results In the third quarter, the company's first full quarter of sales, 204 new patients started treatment on IBT
Show less
Read more
Impact Snapshot
Event Time:
NUVB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NUVB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NUVB alerts
High impacting Nuvation Bio Inc. Class A news events
Weekly update
A roundup of the hottest topics
NUVB
News
- Nuvation Bio Inc. (NUVB) Announces Exclusive Licensing Agreement With Eisai to Expand Global Reach of Taletrectinib [Yahoo! Finance]Yahoo! Finance
- A Look At Nuvation Bio (NUVB) Valuation After The Eisai Taletrectinib Licensing Deal [Yahoo! Finance]Yahoo! Finance
- Nuvation Bio (NYSE:NUVB) had its price target lowered by analysts at HC Wainwright from $18.00 to $17.00. They now have a "buy" rating on the stock.MarketBeat
- Nuvation Bio says preliminary Q4 and FY25 IBTROZI net product revenue was $15.7M and $24.7M [Seeking Alpha]Seeking Alpha
- Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire
NUVB
Earnings
- 11/3/25 - Beat
NUVB
Sec Filings
- 1/12/26 - Form 8-K
- 12/3/25 - Form 4
- 12/1/25 - Form 144
- NUVB's page on the SEC website